Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmacologically acceptable salt thereof: wherein two R moieties each independently are a C1-3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group; A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and R1, R2 and R3 each independently are an optionally substituted linear or branched C1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.

Abstract: The present invention provides a compound having Keap1 inhibitory effects and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein the symbols have the same meanings as those described in the description] or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

Abstract: A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a C1-3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group; A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and R1, R2 and R3 each independently are an optionally substituted linear or branched C1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.

Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

Abstract: A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a C1-3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group; A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and R1, R2 and R3 each independently are an optionally substituted linear or branched C1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.

Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.

Abstract: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

Abstract: Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.